Abstract 192P
Background
Neoadjuvant chemotherapy is the best option for most epithelial ovarian cancers as they present in stage III & IV.The important determinants of survival in ovarian cancer include complete cytoreduction and response to platinum based chemotherapy . HE4, a novel biomarker was found to be better predictor of optimal cytoreduction and platinum sensitivity compared to CA 125 which has low sensitivity and specificity in premenopausal women. This study is done to assess the role of serum marker HE4 in predicting response to chemotherapy in epithelial ovarian cancer.
Methods
This is a prospective observational study of 39 patients in the age group 25-75yrs with newly diagnosed epithelial ovarian cancer/primary peritoneal carcinoma planned for neo adjuvant chemotherapy. Patients with renal failure and other cancers which can cause HE4 elevation were excluded. Tumour markers CA125 and HE4 were measured at baseline, before each cycle of chemotherapy and before surgery. Imaging with CECT abdomen was done at the end of neo adjuvant chemotherapy. The prediction of response by the tumour markers were assessed.
Results
Most patients were postmenopausal with high grade serous adenocarcinoma histology, in advanced stage(FIGO 3 or 4). Tumour markers did not predict radiological outcomes. Optimal cytoreduction(R0-≤ 1cm residual disease) was achieved in 66.7%. Neither CA125 nor its reduction with chemotherapy was predictive of surgical outcome. HE4 at the end of NACT and its reduction with chemotherapy was predictive of optimal cytoreduction. HE4 cut off of 275pmol/L at the end of NACT had 77% sensitivity and 85% specificity to predict poor surgical outcome. Reduction in HE4 with chemotherapy was a predictor of pathological response. Table: 192P
Baseline | Cycle 1 | Cycle 2 | Cycle 3 | End of NACT | ||||||
Marker | CA 125 | HE 4 | CA 125 | HE 4 | CA 125 | HE 4 | CA 125 | HE 4 | CA 125 | HE 4 |
%Reduction (R+) | 43 | 30 | 73 | 55 | 83 | 66 | 86 | 71 | ||
%Reduction (R0) | 48 | 48 | 75 | 73 | 86 | 86 | 88 | 88 | ||
p-value | >0.05 | <0.01 | >0.05 | <0.01 | >0.05 | <0.01 | >0.05 | <0.01 | ||
R+ | 1924.95 | 2121.6 | 911.45 | 1321 | 281.23 | 833.6 | 168.45 | 580.3 | 164.33 | 522.0 |
R0 | 1470.66 | 2366.8 | 813.34 | 1147.7 | 330.1 | 562.5 | 153.73 | 287.1 | 126.22 | 172.3 |
p-value | >0.05 | >0.05 | >0.05 | >0.05 | >0.05 | >0.05 | >0.05 | <0.05 | >0.05 | <0.01 |
Conclusions
HE4 is a better predictor of response to therapy in patients undergoing neo adjuvant chemotherapy. HE4 value at the end of NACT and percentage reduction with each cycle can predict optimal cytoreduction after neo adjuvant chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sarada Planjery.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
140P - Lenvatinib + everolimus in mRCC that has progressed on immunotherapy: A real-world single center experience
Presenter: CHINNU JOMI
Session: Poster viewing 03
141P - Real-world study of cabozantinib treatment of advanced renal cell carcinoma in Taiwan
Presenter: Yu-Chieh Tsai
Session: Poster viewing 03
143P - Clinical outcomes of systemic therapy for hemodialysis patients with metastatic renal cell carcinoma
Presenter: Shun Iwasa
Session: Poster viewing 03
144P - Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
Presenter: Takanori Hayase
Session: Poster viewing 03
145P - Treatment outcomes and FGFR alterations in unresectable locally advanced or metastatic urothelial cancer in Taiwan
Presenter: Jian-Ri Li
Session: Poster viewing 03
146P - Comparison of the survival outcomes between primary and secondary muscle-invasive bladder cancer: A propensity score-matched Chinese cohort
Presenter: WAICHAN LOK
Session: Poster viewing 03
Resources:
Abstract
147P - Activity of single-agent PD-1/PD-L1 inhibitors in 1st-line (1L) “platinum-ineligible” patients (pts) with metastatic urothelial cancer (mUC) in real-life clinical practice
Presenter: Javier Molina Cerrillo
Session: Poster viewing 03
149P - A need for clear definitions and improved management for BCG-unresponsive tumors in Asia-Pacific
Presenter: Lui Shiong Lee
Session: Poster viewing 03
Resources:
Abstract